eMed Technologies

Executive Summary

eMed Technologies is a US-based digital health and diagnostics company specializing in subcutaneous infusion and drug delivery systems for biologics and specialty drugs. Founded in 2015 and headquartered in Cambridge, Massachusetts, the company aims to empower patient independence through safe, efficient, and user-friendly devices. eMed offers end-to-end services from device development to final packaging, supporting drug commercialization for biopharmaceutical partners. With the rising demand for self-administered biologics, eMed is well-positioned to capture growth in the drug delivery market, which is expected to exceed $20 billion by 2030. The company's platform addresses critical needs for enhanced patient adherence and reduced healthcare costs, differentiating itself through integrated digital health capabilities and a focus on complex drug formulations.

Upcoming Catalysts (preview)

• Q3 2026Partnership with Top 20 Biopharma for Drug-Device Combination Product60% success
• Q4 2026FDA 510(k) Clearance for Next-Generation Subcutaneous Infusion Pump65% success
• Q2 2026Series B Funding Round Exceeding $50 Million55% success